This is a preprint.
Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases
- PMID: 39803488
- PMCID: PMC11722430
- DOI: 10.1101/2025.01.01.631020
Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases
Update in
-
Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.Vaccine. 2025 May 22;56:127157. doi: 10.1016/j.vaccine.2025.127157. Epub 2025 Apr 21. Vaccine. 2025. PMID: 40262372 Free PMC article.
Abstract
The discovery of broadly protective antibodies to the influenza virus neuraminidase (NA) has raised interest in NA as a vaccine target. However, recombinant, solubilized tetrameric NA ectodomains are often challenging to express and isolate, hindering the study of anti-NA humoral responses. To address this obstacle, we established a panel of 22 non-adherent cell lines stably expressing native, historical N1, N2, N3, N9, and NB NAs anchored on the cell surface. The cell lines are barcoded with fluorescent proteins, enabling high-throughput, 16-plex analyses of antibody binding with commonly available flow cytometers. The cell lines were at least as efficient as a Luminex multiplex binding assay at identifying NA antibodies from a library of unselected clonal IgGs derived from human memory B cells. The cell lines were also useful for measuring the magnitude and breadth of the serum antibody response elicited by experimental infection of rhesus macaques with influenza virus. The membrane-anchored NAs are catalytically active and are compatible with established sialidase activity assays. NA-expressing K530 cell lines therefore represent a useful tool for studying NA immunity and evaluating influenza vaccine efficacy.
Conflict of interest statement
Declaration of competing interests EBW has received research funding from Pfizer, Moderna, Seqirus, Najit Technologies, and Clinetic for the conduct of clinical research studies. He has also received support as an advisor to Vaxcyte and Pfizer, as a consultant to ILiAD Biotechnologies, and as DSMB member for Shionogi. The other authors have no competing interests to declare.
Figures
References
-
- Caini S. et al. , Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases. Lancet Microbe 5, 100851 (2024). - PubMed
-
- Monto A. S., Zambon M., Weir J. P., The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent Vaccines. N Engl J Med 390, 1256–1258 (2024). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources